Altiratinib blocks Toxoplasma gondii and Plasmodium falciparum development by selectively targeting a spliceosome kinase | Science Translational Medicine
Spliceosome targeting by altiratinib leads to Toxoplasma and Plasmodium inhibition.
Spliceosome targeting by altiratinib leads to Toxoplasma and Plasmodium inhibition.